Core Viewpoint - The approval of Indobufen tablets by the National Medical Products Administration enhances the company's product line in cardiovascular medications and strengthens its market competitiveness [1][2]. Company Summary - The company has received the drug registration certificate for Indobufen tablets, which is a platelet aggregation inhibitor used primarily for ischemic cardiovascular and cerebrovascular diseases, as well as for preventing thrombosis during hemodialysis [1]. - The approval of Indobufen tablets enriches the company's existing portfolio of cardiovascular drugs, which includes products like Ezetimibe tablets, Irbesartan Hydrochlorothiazide tablets, and others [2]. - The company’s cardiovascular drugs have already captured a certain market share, and the new approval is expected to improve overall profitability [2]. Industry Summary - The demand for cardiovascular medications has created a substantial market, leading to significant opportunities for companies in this sector [2]. - The approval of Indobufen tablets does not require further consistency evaluation, aligning with the regulations set forth in the relevant government document [2].

Core Viewpoint - The approval of Indobufene tablets by the National Medical Products Administration enhances the company's product line in the cardiovascular drug market and strengthens its competitive position, potentially improving overall profitability [1][2]. Company Summary - The company has received the drug registration certificate for Indobufene tablets, which is a platelet aggregation inhibitor used for ischemic cardiovascular diseases and venous thrombosis [1]. - Indobufene works by reversible inhibition of platelet cyclooxygenase, reducing the generation of thromboxane B2, and inhibiting platelet aggregation induced by various factors [1]. - The company has a range of cardiovascular drugs already approved and marketed, including Ezetimibe tablets and Erbesartan Hydrochlorothiazide tablets, contributing to its market share [2]. Industry Summary - The demand for cardiovascular medications has created a substantial market, and the company’s ongoing research and market development efforts have allowed it to capture a significant share [2]. - The approval of Indobufene tablets not only enriches the company's product line but also enhances its competitiveness in the cardiovascular drug market [2]. - The company is not required to conduct consistency evaluations for the newly approved Indobufene tablets, according to relevant regulations [2].